FDA panel backs Grail's Galleri multi-cancer blood test, citing benefit-risk profile

An FDA advisory committee voted that the benefits of Grail's Galleri multi-cancer screening blood test outweigh its risks, a key step toward potential approval. The endorsement is non-binding but likely to influence the FDA's final decision. Approval would expand multi-cancer early detection (MCED) screening in the US, though questions remain on clinical utility and follow-up protocols.